# Shennon Biotechnologies

> Shennon Biotechnologies is a San Francisco biotech turning immune-cell target discovery from a months-long slog into a same-day job. Its proprietary TCELERATOR platform fuses ultra-high-throughput microfluidics with AI to functionally profile millions of single immune cells in hours, pinpointing the rare T and B cells that recognize cancer antigens. Founded in 2021 by physicist-turned-founder Li Sun, the company is building a pipeline of validated targets for solid tumors and autoimmune disease, backed by a $13M seed round led by DCVC.

- **Founded:** 2021
- **Headquarters:** San Francisco, United States
- **Founders:** Li Sun (Founder & CEO)
- **Team size:** ~16
- **Products:** TCELERATOR, Immunotherapy target discovery, Cell therapy & engager development
- **Notable:** Closed an oversubscribed $13M seed round led by DCVC in March 2023, Developed the TCELERATOR platform capable of functionally profiling millions of immune cells at single-cell resolution in hours instead of weeks or months, Assembled a scientific advisory bench spanning microfluidics and immunotherapy (including David Weitz, Joseph Fraietta, Michael Kalos, Kristen Hege)

## Products & services

- **TCELERATOR** — A proprietary ultra-high-throughput single-cell functional screening platform that combines microfluidic biochips with AI models to profile millions of single cell-cell interactions simultaneously, isolating functionally activated rare T and B cells and their cognate antigens within hours.
- **Immunotherapy target discovery** — Identification and validation of TCR and antibody targets for solid tumors and autoimmune disease, including neoantigen/neoepitope prediction and TCR-pMHC interaction modeling.
- **Cell therapy & engager development** — Applying discovered targets toward next-generation cell therapies, T cell engagers, and bispecific antibodies against difficult indications.

## Achievements

- Closed an oversubscribed $13M seed round led by DCVC in March 2023
- Developed the TCELERATOR platform capable of functionally profiling millions of immune cells at single-cell resolution in hours instead of weeks or months
- Assembled a scientific advisory bench spanning microfluidics and immunotherapy (including David Weitz, Joseph Fraietta, Michael Kalos, Kristen Hege)

## Latest updates

- **2023-03** — Announced $13M seed financing led by DCVC to expand the platform and scale discovery of targets for solid tumors.
- **2025-11** — Presence at SITC 2025 (Society for Immunotherapy of Cancer), signaling continued immuno-oncology research output.

## Links

- Website: https://shennonbio.com
- LinkedIn: https://www.linkedin.com/company/shennon-bio

---

Profile page: https://yespress.io/shennon-biotechnologies
Published by YesPress — https://yespress.io
Last updated: 2026-07-02